IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis
Abstract Background Alcohol consumption causes a spectrum of liver abnormalities and leads to over 3 million deaths per year. Alcoholic hepatitis (AH) is a florid presentation of alcoholic liver disease characterized by liver failure in the context of recent and heavy alcohol consumption. The aim of...
Enregistré dans:
Auteurs principaux: | N. Vergis, V. Patel, K. Bogdanowicz, J. Czyzewska-Khan, F. Fiorentino, E. Day, M. Cross, N. Foster, E. Lord, R. Goldin, E. Forrest, M. Thursz |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMC
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f45e5e1c18fb4154a6fd28e5c0c832cd |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Baseline renal functions predict the effect of canakinumab on regression of proteinuria in patients with familial Mediterranean fever
par: Tolga Yildirim, et autres
Publié: (2021) -
The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
par: Kacar M, et autres
Publié: (2020) -
Muckle–Wells syndrome: clinical perspectives
par: Tran TA
Publié: (2017) -
Severe alcoholic hepatitis: current perspectives
par: Philips CA, et autres
Publié: (2019) -
Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis
par: Mengfei Liu, et autres
Publié: (2021)